Now that Phathom Pharmaceuticals Inc’s volume has hit 0.77 million, investors get a glimpse of its size.

A new trading day began on Monday, with Phathom Pharmaceuticals Inc (NASDAQ: PHAT) stock price up 3.47% from the previous day of trading, before settling in for the closing price of $8.35. PHAT’s price has ranged from $2.21 to $19.71 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Annual sales at Healthcare sector company grew by 12.50% over the past five years. Meanwhile, its annual earnings per share averaged 41.47%. With a float of $37.85 million, this company’s outstanding shares have now reached $69.64 million.

Let’s look at the performance matrix of the company that is accounted for 427 employees. In terms of profitability, gross margin is 86.23%, operating margin of -349.84%, and the pretax margin is -307.2%.

Phathom Pharmaceuticals Inc (PHAT) Insider Updates

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Phathom Pharmaceuticals Inc is 45.79%, while institutional ownership is 47.37%. The most recent insider transaction that took place on Jul 16 ’25, was worth 14,152. In this transaction Principal Accounting Officer of this company sold 1,692 shares at a rate of $8.36, taking the stock ownership to the 48,392 shares. Before that another transaction happened on May 21 ’25, when Company’s Director bought 3,780 for $3.86, making the entire transaction worth $14,609. This insider now owns 59,403 shares in total.

Phathom Pharmaceuticals Inc (PHAT) Performance Highlights and Predictions

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.56 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 41.47% per share during the next fiscal year.

Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators

Here are Phathom Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.37.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.24, a number that is poised to hit -0.95 in the next quarter and is forecasted to reach -0.42 in one year’s time.

Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)

Phathom Pharmaceuticals Inc (NASDAQ: PHAT) saw its 5-day average volume 0.73 million, a negative change from its year-to-date volume of 1.82 million. As of the previous 9 days, the stock’s Stochastic %D was 35.21%.

During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 63.60%, which indicates a significant increase from 42.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.63 in the past 14 days, which was lower than the 0.68 volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $8.20, while its 200-day Moving Average is $7.73.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.